Revumenib (SNDX-5613)

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biotech focused on developing novel inhibitors for cancers with high unmet need, primarily through its menin and BET inhibitor platforms. Its lead asset, revumenib, is a potential best-in-class menin inhibitor in late-stage development for KMT2A-rearranged and NPM1-mutant acute leukemias. The company's strategy leverages deep mechanistic insight to target key drivers of oncogenesis and fibrosis, aiming to deliver transformative therapies. With a disciplined approach to clinical development and a strong cash position, Syndax is advancing a targeted pipeline toward key regulatory milestones.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biotech focused on developing novel inhibitors for cancers with high unmet need, primarily through its menin and BET inhibitor platforms. Its lead asset, revumenib, is a potential best-in-class menin inhibitor in late-stage development for KMT2A-rearranged and NPM1-mutant acute leukemias. The company's strategy leverages deep mechanistic insight to target key drivers of oncogenesis and fibrosis, aiming to deliver transformative therapies. With a disciplined approach to clinical development and a strong cash position, Syndax is advancing a targeted pipeline toward key regulatory milestones.

Therapeutic Areas